6533b863fe1ef96bd12c78e7
RESEARCH PRODUCT
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
Francesca IannantuoniNoelia Diaz-moralesVictor M. VictorZaida Abad-jiménezCelia BañulsSusana Rovira-llopisAntonio Hernández-mijaresRosa FalcónAranzazu M. De Marañónsubject
Antioxidantleukocytesmedicine.medical_treatmentempagliflozinlcsh:MedicineInflammationType 2 diabetes030204 cardiovascular system & hematologyPharmacologySystemic inflammationmedicine.disease_causeArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineEmpagliflozinoxidative stress030304 developmental biology0303 health sciencesbiologybusiness.industrylcsh:RGeneral MedicineGlutathionemedicine.diseasechemistryinflammationMyeloperoxidasebiology.proteinsglt2 inhibitorstype 2 diabetesmedicine.symptombusinessOxidative stressdescription
Sodium&ndash
year | journal | country | edition | language |
---|---|---|---|---|
2019-11-01 | Journal of Clinical Medicine |